India Diabetes Market information, by Type (Type 1, Type 2, and Gestational diabetes), by Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others), by Devices (Blood glucose monitoring devices, Diabetes management devices, and others) by Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery and others) - Forecast to 2032

India Diabetes Market Overview

The India diabetes market size was valued at USD 6.75 Billion in 2023 and is projected to grow from USD 6.86 Billion in 2024 to USD 11.46 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.54% during the forecast period (2024 - 2032). Diabetes is a chronic metabolic condition that results in high blood glucose levels, which seriously harms the heart, blood vessels, eyes, kidneys, and nerves. Drugs used to treat diabetes are known as diabetic therapies, which consist of oral diabetes medications and human insulin mimics.

India Diabetes Market Trends

The leading causes of diabetes mellitus in Indians are obesity, particularly central obesity, increased visceral fat brought on by physical inactivity, and diets high in calories, fat, and sugar. The most prevalent work culture that is still practised in the nation, which involves consuming fast food while engaging in little to no physical exercise and spending hours in one position while seated, is a major factor in the rapid rise in diabetes incidence among India's working-age population. Additionally, the rising number of diabetic people and its growing prevalence and expanding use of insulin-delivery and continuous glucose monitoring devices are propelling market expansion. In India, 77 million people were estimated to have diabetes in 2019, and by 2045, that number is expected to reach over 134 million. About 57% of these people are still undiagnosed. However, problems faced by poor individuals across India in managing diabetes care are major restraining factors for the market.

India Diabetes Market Segment Insights 

The said market segment has been segmented based on type which comprises Type 1, Type 2, and Gestational diabetes.

Based on tests, the market is segmented into Random blood sugar tests, Fasting blood sugar tests, Oral glucose tolerance tests, Initial glucose challenge tests and others.

Based on devices, it is segmented into Blood glucose monitoring devices, Diabetes management devices, and others.

Based on treatment, the market is segmented into Medications, Insulin therapy, Transplantation, Bariatric surgery and Blood Sugar Treatment.

India Diabetes Regional Insights 

Considering the scenario of the Indian diabetes market, the western region is believed to be the largest market share holder for diabetes care. Moreover, the Eastern and Northern regions are also growing and the second-largest market for India's Diabetes treatment sector. On the other hand, the Southern Indian market is expected to grow at a significant rate in the Indian diabetes market during the forecasted period. The central region is likely to have limited but moderate growth in the said market segment.

India Diabetes Market Key Players Insights

• Novo Nordisk A/S (Denmark)


• USV Private Limited (India)


• sanofi-aventis U.S


• LLC (US)


• Novartis AG (Switzerland)


• Merck & Co., Inc. (US)


• Becton Dickinson and Company (US)


• Roche Diabetes Care, Inc.(US),


• Johnson & Johnson Services, Inc.(us)


• Bayer AG (Germany)


• Ypsomed (Switzerland)

The report for India Diabetes Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Report Attribute/Metric	Details
Market Size	USD 11.46 billion
CAGR	6.54%
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Type, Test, Devices, Treatment
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Novo Nordisk A/S (Denmark), USV Private Limited (India), sanofi-aventis U.S. LLC (US), Novartis AG (Switzerland), Merck & Co., Inc. (US), Becton Dickinson and Company (US), Roche Diabetes Care, Inc.(US),Johnson & Johnson Services, Inc.(us), Bayer AG (Germany), Ypsomed (Switzerland)
Key Market Opportunities	Research and developments
Key Market Drivers	·  Increasing number of patients·  Increasing urbanization·  Healthcare infrastructure·  Increasing spending on healthcare